CDIO [NASD]
Cardio Diagnostics Holdings, Inc.
Index- P/E- EPS (ttm)- Insider Own19.80% Shs Outstand8.12M Perf Week136.46%
Market Cap19.82M Forward P/E- EPS next Y-0.55 Insider Trans0.00% Shs Float4.39M Perf Month110.19%
Income- PEG- EPS next Q-0.09 Inst Own55.60% Short Float / Ratio1.01% / 0.08 Perf Quarter10.73%
Sales0.00M P/S21994.56 EPS this Y- Inst Trans-6.49% Short Interest0.04M Perf Half Y-77.12%
Book/sh8.02 P/B0.28 EPS next Y36.80% ROA- Target Price8.00 Perf Year-
Cash/sh0.02 P/C99.09 EPS next 5Y- ROE- 52W Range0.80 - 10.25 Perf YTD114.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.85% Beta-
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low184.96% ATR0.34
Employees4 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)76.52 Volatility55.23% 22.82%
OptionableNo Debt/Eq0.01 EPS Q/Q- Profit Margin- Rel Volume2.56 Prev Close1.88
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume576.05K Price2.27
Recom2.00 SMA2092.78% SMA5066.47% SMA200-65.44% Volume1,475,651 Change20.74%
Jan-05-23 08:00AM
Jan-04-23 04:15PM
Dec-28-22 08:00AM
Nov-21-22 08:00AM
Nov-17-22 07:01AM
04:15PM Loading…
Nov-16-22 04:15PM
Nov-14-22 08:13AM
Nov-08-22 07:12AM
Oct-26-22 08:30AM
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.